The interaction between neurotransmitter receptor activity and amyloid-β pathology in Alzheimer's disease
- PMID: 40388923
- PMCID: PMC12283230
- DOI: 10.1177/13872877251342273
The interaction between neurotransmitter receptor activity and amyloid-β pathology in Alzheimer's disease
Abstract
The accumulation of amyloid-β (Aβ) peptides is a hallmark of Alzheimer's disease (AD). Central to AD pathology is the production of Aβ peptides through the amyloidogenic processing of amyloid-β protein precursor (AβPP) by β-secretase (BACE-1) and γ-secretase. Recent studies have shifted focus from Aβ plaque deposits to the more toxic soluble Aβ oligomers. One significant way in which Aβ peptides impair neuronal information processing is by influencing neurotransmitter receptor function. These receptors, including adrenergic, acetylcholine, dopamine, 5-HT, glutamate, and gamma-aminobutyric acid (GABA) receptors, play a crucial role in regulating synaptic transmission, which underlies perceptual and cognitive functions. This review explores how Aβ interacts with these key neurotransmitter receptors and how these interactions contribute to neural dysfunction in AD. Moreover, we examine how agonists and antagonists of these receptors influence Aβ pathology, offering new perspectives on potential therapeutic strategies to curb AD progression effectively and improve patients' quality of life.
Keywords: 5HT; Alzheimer's disease; GABA; acetylcholine; amyloid-β; dopamine; glutamate; neurotransmitter; norepinephrine.
Conflict of interest statement
Declaration of conflicting interestsQ.W. is the co-founder of Sharper Sense, a company developing methods of enhancing sensory processing with neural interfaces.
Similar articles
-
Co-Aggregation of Syndecan-3 with β-Amyloid Aggravates Neuroinflammation and Cognitive Impairment in 5×FAD Mice.Int J Mol Sci. 2025 Jun 8;26(12):5502. doi: 10.3390/ijms26125502. Int J Mol Sci. 2025. PMID: 40564963 Free PMC article.
-
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life.Acta Neuropathol Commun. 2025 May 29;13(1):121. doi: 10.1186/s40478-025-02022-y. Acta Neuropathol Commun. 2025. PMID: 40442822 Free PMC article.
-
Interactions between daily sleep-wake rhythms, γ-secretase, and amyloid-β peptide pathology point to complex underlying relationships.Biochim Biophys Acta Mol Basis Dis. 2025 Aug;1871(6):167840. doi: 10.1016/j.bbadis.2025.167840. Epub 2025 Apr 11. Biochim Biophys Acta Mol Basis Dis. 2025. PMID: 40222459
-
Microglial activation as a hallmark of neuroinflammation in Alzheimer's disease.Metab Brain Dis. 2025 May 17;40(5):207. doi: 10.1007/s11011-025-01631-9. Metab Brain Dis. 2025. PMID: 40381069 Review.
-
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2. Cochrane Database Syst Rev. 2017. PMID: 28328043 Free PMC article.
References
-
- Anderson JP, Esch FS, Keim PS, et al. Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neuroscience letters 1991; 128: 126–128. - PubMed
-
- Wilson CA, Doms RW and Lee VM. Intracellular APP processing and Aβ production in Alzheimer disease. Journal of neuropathology and experimental neurology 1999; 58: 787–794. - PubMed
-
- Burdick D, Soreghan B, Kwon M, et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. Journal of Biological Chemistry 1992; 267: 546–554. - PubMed
-
- Sherrington R, Rogaev E, Liang Ya, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995; 375: 754–760. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical